TY - JOUR T1 - Synergistic Benefit of Adoptive T Cells in Combination With Chemoradiotherapy Against Metastatic Prostate Cancer Cells JF - Anticancer Research JO - Anticancer Res SP - 3427 LP - 3434 DO - 10.21873/anticanres.15829 VL - 42 IS - 7 AU - YUN-CHU SHEN AU - HUNG-JEN SHIH AU - CHI-CHIEN LIN AU - SHENG-HSIEN HUANG AU - SHENG-CHUAN WU AU - CHI-HAO HSIAO AU - SHAO-CHI CHIU AU - DER-YANG CHO AU - CHIN-PAO CHANG AU - YUEH PAN AU - PING-HSIAO SHIH Y1 - 2022/07/01 UR - http://ar.iiarjournals.org/content/42/7/3427.abstract N2 - Background/Aim: Prostate cancer (PC) is one of the major diseases that affects male health and ranks as the second most frequent cancer in men worldwide. Although most newly-diagnosed PCs are well-differentiated tumors with a high cure probability, there are some patients with aggressive malignancies that show potential for recurrence and metastasis. Cytotoxic T lymphocytes are a specific immune effector cell population that mediates immune responses against cancer. Materials and Methods: In the present study, the cytotoxicity of peripheral blood mononuclear cells (PBMCs)-derived γδ T cells and cytokine-induced killer (CIK) cells in combination with chemoradiotherapy against PC cells was evaluated using Alamar blue cell viability and cell membrane permeability assays. Results: Advanced PC-3 cells, which were more resistant to docetaxel (Doc), also showed higher viability following pretreatment with radiation. The cell proliferation inhibition was significantly increased upon additional γδ T or CIK treatment. Furthermore, the proportion of apoptotic cells was significantly (p<0.05) increased in the Doc-γδ T cell co-treatment group as compared with the Doc or γδ T cell treated alone group. Conclusion: γδ T cell therapy may provide additional benefit compared to traditional chemoradiotherapy for PC treatment. ER -